About arcutis biotherapeutics inc - ARQT
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.
ARQT At a Glance
Arcutis Biotherapeutics, Inc.
3027 Townsgate Road
Westlake Village, California 91361
| Phone | 1-805-418-5006 | Revenue | 196.54M | |
| Industry | Pharmaceuticals: Major | Net Income | -140,039,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 229.735% | |
| Fiscal Year-end | 12 / 2025 | Employees | 342 | |
| View SEC Filings |
ARQT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 8.573 |
| Price to Book Ratio | 10.42 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -12.456 |
| Enterprise Value to Sales | 7.973 |
| Total Debt to Enterprise Value | 0.071 |
ARQT Efficiency
| Revenue/Employee | 574,684.211 |
| Income Per Employee | -409,470.76 |
| Receivables Turnover | 2.69 |
| Total Asset Turnover | 0.569 |
ARQT Liquidity
| Current Ratio | 4.145 |
| Quick Ratio | 3.966 |
| Cash Ratio | 2.821 |
ARQT Profitability
| Gross Margin | 90.268 |
| Operating Margin | -65.328 |
| Pretax Margin | -70.922 |
| Net Margin | -71.251 |
| Return on Assets | -40.576 |
| Return on Equity | -113.757 |
| Return on Total Capital | -52.229 |
| Return on Invested Capital | -49.911 |
ARQT Capital Structure
| Total Debt to Total Equity | 70.194 |
| Total Debt to Total Capital | 41.244 |
| Total Debt to Total Assets | 31.696 |
| Long-Term Debt to Equity | 69.674 |
| Long-Term Debt to Total Capital | 40.938 |